Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients
This is a IIa phase IIa open-label, non-randomized clinical trial of Antroquinonol, capsule, 100 mg (Golden Biotechnology Corporation, Taiwan) in patients with AML.
Leukemia, Myeloid, Acute
DRUG: Antroquinonol
Complete blood count measurements according International Working Group (IWG) response criteria, Evaluation of preliminary efficacy profile of antroquinonol in adult patients with relapsed AML or at initial diagnosis when no intensive treatment is possible., 2 weeks
Number of Participants alive at 4weeks, patients' situation, 4 weeks|Number of Participants alive at 24 weeks, patients' situation, 24 weeks
The given pilot clinical trial of a medicinal product for medical use, is held to evaluate preliminary efficacy and safety/tolerability profiles of antroquinonol in adult patients with relapsed AML or at initial diagnosis when no intensive treatment is possible.